Author： Doggrell Sheila A
Publisher： Informa Healthcare
ISSN： 1465-6566
Source： Expert Opinion on Pharmacotherapy, Vol.2, Iss.11, 2001-11, pp. : 1919-1920
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Osteoporosis is a major public health problem for older women and men. Parathyroid hormone (PTH) (1-34), which produces similar biological activity to the parent hormone, was tested in postmenopausal women with prior vertebral fractures. In 18 months, PTH (1-34) caused a dramatic 65% decrease in the risk of new vertebral fractures with a 10% increase in bone mineral density with few side effects. PTH (1-34) represents an exciting new therapy for this high risk group.
Related content
Parathyroid Hormone An Anabolic Treatment for Osteoporosis.
Current Pharmaceutical Design, Vol. 7, Iss. 8, 2001-05 ,pp. :
Access to resources
Recommend
Parathyroid hormone, alendronic acid: no synergy in osteoporosis
Inpharma, Vol. 1, Iss. 1407, 2003-01 ,pp. :